Price movement over the last 24 hours
ADMA Biologics Inc vs Zillow Group Inc Class A — how do they compare? ADMA Biologics Inc trades at $9.23 (market cap $2.13B), while Zillow Group Inc Class A trades at $31.74 (market cap $7.50B). The key difference: Zillow Group Inc Class A is far larger — about 3.5× ADMA Biologics Inc's market cap. Which is the better fit depends on your goals.
| ADMA | ZG | |
|---|---|---|
Market Cap | $2.13B | $7.50B |
Sector | Health | Media |
52-Week High | $20.38 | $86.76 |
52-Week Low | $7.60 | $29.14 |
Enterprise Value | $2.20B | $7.14B |
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
Zillow Group (ZG) trades at $32.69, down 2.18% on the day, with a mixed technical outlook showing a bullish overall signal but bearish moving averages. The company reported revenue of $2.58 billion for 2025 with a net income of $23 million, marking a return to profitability after losses in prior years. Recent news is dominated by multiple securities class action lawsuits alleging anticompetitive conduct, creating significant headline risk.
The investment outlook is clouded by legal overhangs despite positive earnings beats and a consensus analyst price target of $57.80 implying substantial upside. Key risks include the outcome of litigation and the sustainability of recent margin improvements. The high P/E ratio of 131.8 suggests growth expectations are already priced in, demanding flawless execution.
Trailing returns across standard periods
Latest headlines on both assets
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →Zillow Group is an Internet-based real estate company that has historically focused on deriving ad revenue from third-party brokers on online marketplaces such as Zillow.com, Trulia, and HotPads. More recently it has shifted its focus to iBuying via the Zillow Offers platform.
Read more on ZG →